Research programme: gene editing therapeutics - CRISPR Therapeutics

Drug Profile

Research programme: gene editing therapeutics - CRISPR Therapeutics

Alternative Names: CRISPR-Cas9 gene therapies; CTX 001

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CRISPR Therapeutics
  • Developer CRISPR Therapeutics; Genethon; University of Alabama at Birmingham; University of Florida; Vertex Pharmaceuticals
  • Class Antianaemics; Antidementias; Antineoplastics; Gene therapies; Neuropsychotherapeutics; Stem cell therapies
  • Mechanism of Action Gene modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Beta-thalassaemia; Cancer; Haemoglobinopathies; Mucopolysaccharidosis I; Sickle cell anaemia
  • Research Amyotrophic lateral sclerosis; Cystic fibrosis; Dementia; Duchenne muscular dystrophy; Friedreich's ataxia; Glycogen storage disease type I; Unspecified

Most Recent Events

  • 12 Dec 2017 Preclinical data in Beta-thalassaemia and Sickle cell anaemia presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2017)
  • 07 Dec 2017 CRISPR Therapeutics files a Clinical Trial Application with the EMA in the European Union for Beta-thalassaemia
  • 07 Dec 2017 CRISPR Therapeutics plans a phase I/II trial of CTX 001 for Beta-thalassaemia in Europe in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top